近期份额规模变动情况： 日期期间申购（亿份）期间赎回（亿份）期末总份额（亿份）期末净资产（亿元）净资产变动率2025- 06-300.000.010.020.02-24.80%2025-03-310.000.000.020.02-2.54%2024-12-310.000.020.020.02-47.96%2024- 09-300.000.020.040.04-27.77% 截至2025年6月30日，中加基金旗下中加医疗创新混合发起式C（016757）期末净资产0.02亿元，比上期 减少41.57%，该基金经理为薛杨。 数据显示，该基金近3个月收益率0.34%，近一年收益率3.53%，成立以来收益率为-19.91%。其股票持 仓前十分别为：联影医疗、天坛生物、迈瑞医疗、开立医疗、金域医学、派林生物、华特达因、鱼跃医 疗、聚光科技、春立医疗，前十持仓占比合计71.19%。 简历显示，薛杨先生:北京大学生药学硕士。2018年7月加入北京泓澄投资管理有限公司任研究员,2020 年9月加入中海基金管理有限公司任分析师。2022年1月加入中加基金管理有限公司。现担任中加医疗创 新混合型发起式证券投资基金(2022年11月 ...

Investment Rating - The industry investment rating is maintained at "Outperform the Market" [1] Core Insights - The analysis indicates a continuous recovery in the heavy positions of pharmaceutical funds, with innovative drugs being the most recognized direction for increased investment [1][8] - In Q2 2025, the overall heavy position of pharmaceutical funds increased, with public funds' pharmaceutical heavy position at 9.8%, up by 0.7 percentage points from the previous quarter [3][13] - The total scale of pharmaceutical funds reached 338.5 billion yuan, reflecting a 3.7% increase quarter-on-quarter [24] Fund Holdings Overview - In Q2 2025, the heavy position of all public funds in the pharmaceutical sector rose, with active funds showing a heavier allocation compared to non-pharmaceutical funds [3][13] - The heavy position of pharmaceutical active funds accounted for 32% of the total heavy position market value in the pharmaceutical sector, while non-pharmaceutical active funds accounted for 34% [17][24] - The total number of pharmaceutical fund shares was 610.6 billion, down by 3.8% from the previous quarter [24] Sector Breakdown - The overall holding ratios for different sectors in the pharmaceutical industry showed varied changes, with Pharma, Bio-Tech, and Bio-Pharma seeing increases, while CXO and specialized chains experienced declines [7][10] - The holding ratio for Pharma increased by 0.39 percentage points, while Bio-Tech saw an increase of 0.21 percentage points [7][32] - The top three sectors with increased holdings in public funds were Bio-Pharma, Pharma, and Bio-Tech, while CXO, specialized chains, and medical devices saw the largest declines [10][36] Heavy Stock Analysis - The top five stocks by total market value held by all public funds in the pharmaceutical sector were: Heng Rui Medicine (32.1 billion), WuXi AppTec (24.7 billion), Mindray Medical (22.7 billion), Innovent Biologics (15.5 billion), and United Imaging Healthcare (11.9 billion) [10] - The active increase in market value for stocks included Innovent Biologics (+7 billion), Sanofi Biopharma (+6 billion), and Xinli Tai (+3 billion) [10] - The active reduction in market value was led by Aier Eye Hospital (-4.3 billion), WuXi AppTec (-4.2 billion), and Heng Rui Medicine (-2.5 billion) [10]

Group 1: Event Overview - The "2025 China Sci-Tech Innovation Leaders Summit and the 6th Anniversary Forum of the Sci-Tech Innovation Board" will be held on July 25 in Shanghai, focusing on themes of "source innovation and industry leadership" [1] - The summit will include keynote speeches, high-level dialogues, and roundtable discussions on hot topics such as mergers and acquisitions and overseas expansion, aiming to promote the deep integration of technological innovation and capital markets [1] Group 2: Sci-Tech Innovation Board Performance - As of now, there are 589 listed companies on the Sci-Tech Innovation Board, with a total IPO financing amount of approximately 925.7 billion and a total market value exceeding 7 trillion [2] - The board has seen significant R&D investment, with a cumulative amount of 168.1 billion in 2024, which is more than three times the net profit attributable to the parent company [2] - The three strategic emerging industries—new generation information technology, biomedicine, and high-end equipment manufacturing—account for over 80% of the board's market value [2] Group 3: Market Trends and Investment Opportunities - The current trend of de-globalization and the urgent need for self-sufficiency have heightened the necessity for the development of new productive forces, with the Sci-Tech Innovation Board focusing on hard technology sectors such as electronic chips and biomedicine [3] - Investment directions represented by Sci-Tech Chip ETF (588290), Sci-Tech Information ETF (588260), and Sci-Tech 50 ETF Index Fund (588280) are worth long-term attention [3] Group 4: Recent Market Performance - The overall performance of the Sci-Tech Innovation Board has seen an increase, with the Sci-Tech 50 Index rising by 1.32%, the Sci-Tech Information Index by 0.88%, and the Sci-Tech Chip Index by 0.12% over the past week [4] - The top five industries on the Sci-Tech Innovation Board—electronics, biomedicine, computers, power equipment, and machinery—account for 87.2% of the board's total market value [5] Group 5: Sector Insights - In the new generation information technology sector, AI hardware, particularly optical modules, has seen a collective surge, driven by strong mid-year performance and increased global demand for AI computing power [7] - The high-end equipment manufacturing sector is experiencing significant growth, with industrial robot exports increasing by 61.5% year-on-year, and forklift sales up by 23.1% [8] - The innovative drug market is also on the rise, with the industry transitioning from "follower" to "leader," and 2025 expected to be a pivotal year for the emergence of blockbuster drugs [8]

Market Overview - The Shanghai Composite Index is at 3570.20 points, above the six-month moving average, with a change of 0.29% [1] - The total trading volume of A-shares today is 15610.05 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 61 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Huabei Mining: 8.00% deviation rate, with a price increase of 8.60% [1] - Hengjin Induction: 7.25% deviation rate, with a price increase of 8.04% [1] - Shanmei International: 7.00% deviation rate, with a price increase of 10.04% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Juhua Technology: minor deviation rate [1] - *ST Chuntian: minor deviation rate [1] - Hanzhong Precision Machinery: minor deviation rate [1]

Core Viewpoint - The article highlights the strong performance of the Yajiang Hydropower Station concept stocks and the short-term rise of CATL's A and H shares, indicating a bullish sentiment in the market [1][12]. Market Overview - On July 22, the A-share market saw a slight increase, with the Shanghai Composite Index rising by 0.25% to 3568.78 points, the Shenzhen Component Index up by 0.56% to 11069.57 points, and the ChiNext Index increasing by 0.69% to 2312.74 points [1]. - The total trading volume in the Shanghai and Shenzhen markets exceeded 1.14 trillion yuan, an increase of 513 billion yuan compared to the previous trading day [4]. Sector Performance - The infrastructure sector experienced a significant rally, with concepts related to hydropower construction, cement manufacturing, and large-scale infrastructure leading the gains. Notably, stocks related to the Yajiang Hydropower Station and water conservancy projects remained hot [4][5]. - Conversely, sectors such as the internet, insurance, and banking saw overall declines, with specific stocks like PEEK materials and Yushun Robotics underperforming [4]. Notable Stocks - The Yajiang Hydropower Station concept stocks saw explosive growth, with over 20 stocks hitting the daily limit up, including companies like China Power Construction and Poly United [10][11]. - CATL's A shares rose nearly 3%, accumulating over 8% in the last three days, while its H shares increased nearly 3%, with a total rise of over 14% in the same period [13]. Special Mention - The Science and Technology Innovation Board (STAR Market) celebrated its sixth anniversary, having accepted 589 companies with a total market capitalization of nearly 8 trillion yuan, showcasing its role in China's capital market reform [18].

Group 1: ETF Performance - The liquidity of the Kexin Pharmaceutical ETF (嘉实) showed an intraday turnover of 18.19%, with a transaction volume of 40.9491 million yuan, indicating active market trading [3] - Over the past week, the Kexin Pharmaceutical ETF (嘉实) experienced a scale increase of 16.9597 million yuan, ranking first among comparable funds [3] - The Kexin Pharmaceutical ETF (嘉实) saw a share increase of 7.5 million shares over the past week, also ranking first among comparable funds [3] - As of July 21, the Kexin Pharmaceutical ETF (嘉实) has achieved a net value increase of 43.45% over the past year, placing it in the top 16.56% among 2,929 index equity funds [3] Group 2: Stock Performance - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading stocks including 联影医疗 (9.73%), 百济神州 (6.04%), and 惠泰医疗 (5.69%) [5][3] - The highest monthly return since inception for the Kexin Pharmaceutical ETF (嘉实) was 23.29%, with the longest consecutive monthly increase being 5 months and an average monthly return of 7.43% [3] Group 3: Market Trends - Huazhong Securities maintains a bottom-up view of the pharmaceutical sector, emphasizing the importance of hard technology innovations, particularly in innovative drugs and devices, which are becoming market hotspots [6] - The recent announcement from the Shanghai Sunshine Pharmaceutical Procurement Network regarding the 11th batch of national centralized procurement includes 55 drug varieties, with key principles focusing on stability, quality assurance, and anti-competitive practices [5]

Core Viewpoint - The medical device sector is showing strong performance and resilience amidst market fluctuations, with significant investment interest and potential for growth driven by supportive policies and market dynamics [1][3]. Group 1: Market Performance - The medical device index ETF (159898) has recorded four consecutive days of gains, indicating strong market interest and a potential for further upward movement [1]. - Over the past three trading days, the ETF has attracted over 11 million in capital, signaling a clear initiation of investment interest [1]. Group 2: Policy Support - A significant policy, "Measures to Optimize Lifecycle Supervision to Support High-end Medical Device Innovation," was released in July, aimed at enhancing the development of high-end medical devices, including medical robots and AI medical devices [3]. - This policy is expected to streamline approval processes and shorten the profit cycle for companies, potentially matching or exceeding the support seen in the innovative drug sector [3]. Group 3: Domestic Market Opportunities - The announcement by a major player to reject imports of high-end medical devices over 45 million creates a substantial market opportunity for domestic manufacturers, particularly in high-end imaging and artificial organ sectors [6]. - The medical device index ETF covers key domestic companies that are likely to benefit from this shift towards domestic production [6]. Group 4: Market Trends and Projections - Historical data indicates that the medical device sector typically experiences a "front low, back high" performance pattern, with significant revenue growth expected in the third quarter as orders convert into income [8]. - Projections suggest that the overall market size for medical device bidding in China will exceed 80 billion in the first half of 2025, reflecting a year-on-year growth of over 60% [8].

Core Insights - The 2025 Service Trade Fair is expected to attract nearly 760 companies, with 47 companies planning to launch over 70 new products and innovations [1] - The fair serves as a significant platform for global companies to showcase digital technology and innovation, facilitating international cooperation and communication [5][8] - The event is seen as a key opportunity for businesses to engage with government entities and understand policy directions, particularly in sectors like healthcare and technology [5][7] Group 1 - The fair is anticipated to enhance international cooperation and provide a platform for companies to expand their networks and share development opportunities [6][9] - Companies like Alibaba and AstraZeneca view the fair as a vital venue for showcasing their innovations and engaging in meaningful dialogues with stakeholders [5][8] - The event is recognized as a benchmark for digital transformation in the service industry, promoting the integration of technology and services [7] Group 2 - Participants express a desire for the fair to facilitate greater international trade and cooperation, particularly for foreign enterprises entering the Chinese market [9][10] - Suggestions include hosting high-quality dialogues between government and enterprises, increasing the visibility of participating companies, and enhancing the overall impact of the fair [9] - The fair is expected to attract influential exhibitors and professionals from around the world, particularly those with significant impact and innovation in the service trade sector [10]

Group 1 - The core viewpoint of the news highlights a positive market reaction to the National Medical Insurance Administration's meeting on supporting innovative drugs and medical devices, leading to a rise in the related stocks of innovative drug companies [1] - The Kexin Biopharmaceutical ETF (588250.SH) increased by 1.08%, with its associated index Kexin Biopharmaceutical (000683.SH) rising by 1.10%, indicating strong market performance [1] - Notable increases in major constituent stocks include: Borui Pharmaceutical up 5.91%, Junshi Biosciences-U up 4.04%, BeiGene-U up 1.74%, and Zai Lab-U up 1.87% [1] Group 2 - Southwest Securities emphasizes the accelerated revaluation of innovative drugs, maintaining a positive outlook on innovative drugs and their supply chain, AI healthcare, and brain-computer interfaces [2] - The life sciences sector is expected to continue expanding, with a strong push for domestic alternatives, exemplified by Aopumai's rapid expansion of its cell culture product pipeline, which has 258 drug research pipelines utilizing its products as of Q1 2025 [2] - CITIC Securities highlights the optimization of centralized procurement rules in the chemical pharmaceutical industry, promoting a shift towards quality competition, with a successful negotiation rate for innovative drugs exceeding 90% [2]

AI基金富国医疗产业混合发起式A（021450）披露2025年二季报，第二季度基金利润15.75万元，加权平均基金份额本期利润0.0147元。报告期内，基金净值 增长率为1.46%，截至二季度末，基金规模为1101.36万元。 该基金属于偏股混合型基金，长期投资于医药医疗股票。截至7月21日，单位净值为1.068元。基金经理是孙笑悦，目前管理3只基金近一年均为正收益。其 中，截至7月21日，富国医药成长30股票近一年复权单位净值增长率最高，达81.88%；富国医疗产业混合发起式A最低，为8.42%。 基金管理人在二季报中表示，本基金旨在差异化深耕医疗器械和医疗服务板块，尤其是医疗器械板块。我们看好国内医疗器械产业的长期发展，虽然其短期 受到医院合规运动的影响、DRGS/DIP 等政策影响，业绩短期承压，但国内医工结合蓬勃发展、制造业和供应链的优势明显，皆有利于国内医疗器械行业的 长足发展。因此我们将继续深挖医疗器械股票标的，继续对该板块保持关注。 通过所选区间该基金净值增长率分位图，可以观察该基金与同类基金业绩比较情况。图为坐标原点到区间内某时点的净值增长率在同类基金中的分位数。 截至6月27日，基金成立以来 ...